Drug intelligence / Profile preview

cyclophosphamide + vincristine + prednisone + dacarbazine

Development stage: Unknown
Lead developer: National Cancer Institute
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A multi-agent chemotherapy regimen consisting of cyclophosphamide, vincristine, prednisone, and dacarbazine. It is primarily utilized in the treatment of Hodgkin lymphoma, particularly in pediatric or relapsed/refractory settings, and has been investigated for neuroblastoma. Cyclophosphamide and dacarbazine act as alkylating agents that damage DNA, vincristine inhibits microtubule formation to arrest mitosis, and prednisone provides lympholytic effects and reduces inflammation.

Brand names: COPDAC-28COPDAC28COPDAC 28
Other names: CVPDCVPD regimen

Targets

TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)DNA

Beyond the preview

Go deeper on cyclophosphamide + vincristine + prednisone + dacarbazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + vincristine + prednisone + dacarbazine.

Explore the full profile